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Abstract
There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and
recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing trials in
animal models; these focus on the manipulation and administration of several growth factors implicated with healing. However,
limitations include in vivo instability, reliance on biocompatible and robust carriers and restricted application procedures (local
and direct). The aim of this paper is therefore to critically review the current literature surrounding the use of BPC 157, as a
feasible therapy for healing and functional restoration of soft tissue damage, with a focus on tendon, ligament and skeletal muscle
healing. Currently, all studies investigating BPC 157 have demonstrated consistently positive and prompt healing effects for
various injury types, both traumatic and systemic and for a plethora of soft tissues. However, to date, the majority of studies have
been performed on small rodent models and the efficacy of BPC 157 is yet to be confirmed in humans. Further, over the past two
decades, only a handful of research groups have performed in-depth studies regarding this peptide. Despite this, it is apparent that
BPC 157 has huge potential and following further development has promise as a therapy to conservatively treat or aid recovery in
hypovascular and hypocellular soft tissues such as tendon and ligaments. Moreover, skeletal muscle injury models have sug-
gested a beneficial effect not only for disturbances that occur as a result of direct trauma but also for systemic insults including
hyperkalamia and hypermagnesia. Promisingly, there are few studies reporting any adverse reactions to the administration of
BPC 157, although there is still a need to understand the precise healing mechanisms for this therapy to achieve clinical
realisation.
Keywords BPC 157 . Bepecin . Pentadecapeptide . Soft tissue injury . Corticosteroid interaction . Angiogenesis . Healing
Introduction
Some of the most frequently injured sites of the human body
involve ‘soft tissues’ including skeletal muscles, tendons and
ligaments. Musculoskeletal injuries of this nature can occur
during both sporting and everyday activities. The majority of
injury complaints, particularly those of a sporting nature, re-
sult from some form of incomplete or complete tear in the
fibres that comprise the structure of the functioning tissue or
‘musculotendinous unit’ (Sloan 2008). The healing capacity
and timelines of recovery for these tissues vary significantly,
depending on several factors. Some of these factors include
the cellular composition and vascular nature of the tissue(s) in
question.
The general healing process can be divided into three
overlapping phases: (1) inflammatory phase (days 1–5), (2)
repair/proliferative phase (days 5–14) and (3) remodelling
phase (days 14–90+) (Hope and Saxby 2007). As an ex-
ample, tendon tissue is composed primarily of tendon fi-
broblastic cells and extracellular matrix, which contains
predominantly type I collagen, type III collagen and gly-
coproteins (Fukuta et al. 1998). Following the remodelling
phase, a higher proportion of synthesised type I collagen, a
corresponding decrease in cellularity, glycosaminoglycan
content and type III collagen (Sharma and Maffulli 2005)
can be observed. This change, coupled with the tissues already
hypocellular and hypovascular nature (Liu et al. 2011), results
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in a ‘slow’ process of healing, particularly when addressing
complete ruptures, which often require surgery. Even after
12 months post-injury or surgical intervention, the tissue still
lacks the biomechanical and ultrastructural characteristics it
had prior to the injury (Fox et al. 2017).
In the USA, figures from 2008 show that 33 million mus-
culoskeletal injuries are reported per year, with 50% involving
ligament and tendon injuries (James et al. 2008). Figures also
show that an estimated 300,000 tendon and ligament repair
surgeries are performed annually in the US alone (Pennisi
2002). Prevalence of injury is also mirrored in professional
sporting populations, with the diagnostic grouping of ‘most
common injury’ as skeletal muscle/tendon in nature, account-
ing for 45% of all diagnosed injuries (Brooks 2005). Thus, the
need for a therapy that can alleviate the social and economic
burden that presents itself with debilitating and recurring soft
tissue injuries is apparent.
Currently, there are several therapies emerging and under-
going trials in animal models that focus on the manipulation
and administration of several growth factors implicated in the
healing process (Halper 2014; Park et al. 2017). However,
limitations exist in the form of in vivo instability, the reliance
on carriers that are biocompatible and robust and limited sites
of application (local and direct) (Park et al. 2017). In compar-
ison, an emerging treatment with potential therapeutic appli-
cation, in the form of a pentadecapeptide known as BPC 157
(body protection compound), appears to be somewhat unre-
stricted by the limitations seen in previous therapies.
The aim of this paper is therefore to critically review the
current literature surrounding the use of BPC 157, as a feasible
therapy for soft tissue healing, with a focus on musculoskele-
tal tissues.
Human gastric juice-derived protein: BPC 157
The human gastric juice-derived protein labelled BPC 157, also
known as Bepecin (Cox et al. 2017), PL 14736 and PL10
(Tkalčević et al. 2007) is a stable gastric pentadecapeptide that
was first introduced and overviewed in the Journal of
Physiology (Paris) by Sikirić et al. (1993). BPC 157 is a 15
amino acid fragment (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-
Asp-Asp-Ala-Gly-Leu-Val) that is often termed as ‘synthetic’;
although the compounds are ‘natural’, they are not known to
exist in nature and are derived from another protein (Bódis et al.
1997). Since these early studies BPC 157 has shown significant
promise in the healing of an abundance of tissues including but
not limited to tendon (Staresinic et al. 2003; Krivic et al. 2006;
Chang et al. 2010), ligaments (Lovric-Bencic et al. 2004;
Cerovecki et al. 2010), skeletal muscle (Staresinic et al. 2006;
Novinscak et al. 2008; Brcic et al. 2009) and bone (Šebečić
et al. 1999). The following sections aim to explore and evaluate
tissue-specific results, with an emphasis on musculoskeletal
soft tissues.
Tendon and ligament healing
Due to a limited blood supply, the spontaneous healing of both
tendons and ligaments is inherently poor. Thus, these soft
tissues are highly prevalent in BPC 157 research. One of the
earlier studies in literature investigated the applicability and
therapeutic efficacy of BPC 157 via intraperitoneal adminis-
tration, specifically the effect of BPC 157 on healing follow-
ing the transection of the Achilles tendon in rats (Staresinic
et al. 2003). It was revealed that, in comparison to the severely
compromised healing observed in sham and control rats, the
systemic delivery of BPC 157 significantly improved recov-
ery measures (Staresinic et al. 2003). This was evidenced bio-
chemically, micro- and macroscopically. Biomechanically, the
healed tendons (over 14 days) showed an increased load to
tendon failure and significantly higher functionality (Achilles
functional Index—AFI). Microscopic analysis revealed a
greater mononuclear count, less granulocytes, an increase in
fibroblasts and superior formation of the reticulin and collagen
fibres. Macroscopically, the defects treated with BPC 157
were smaller in size and depth and subsequently full tendon
integrity was re-established (Staresinic et al. 2003). Similar
results have also been shown in rat models investigating the
healing of the medial collateral ligament (MCL) following
surgical transection (Cerovecki et al. 2010). Treatment of
BPC 157 was administered orally in drinking water, topically
via a thin cream and via intraperitoneal administration over a
90-day period. This suggests that the peptide has a therapeutic
benefit via a wide range of delivery mechanisms (Fig. 1).
A further study investigating tendon-to-bone healing fol-
lowing the transection and detachment of the Achilles tendon
in rats went on to reveal that BPC 157 is also capable of
promoting tendon-to-bone healing despite the presence of cor-
ticosteroids (Krivic et al. 2006). This is of significance since
although corticosteroid use has long been and remains contro-
versial for healing of tissues (Carrico et al. 1984; Walsh et al.
1995; Waters et al. 2000), it still remains a prevalent treatment
choice clinically for soft tissue damage and inflammation.
Thus, the fact that BPC 157 has the apparent ability to coun-
teract corticosteroid aggravation (Krivic et al. 2006) lends
itself to being applied alongside conventional treatments to
improve both understanding and biomechanical outcomes.
Chang et al. (2010) attempted to elucidate the potential
mechanism by which BPC 157 stimulates the outgrowth and
proliferation of tendon fibroblasts. Results showed that BPC
157 significantly accelerated the outgrowth of tendon ex-
plants; furthermore, the in vitro migration and rate of spread-
ing of tendon fibroblasts increased in a dose-dependent man-
ner, which was attributed to the activation of the FAK-paxillin
pathway. Although BPC 157 had no direct effect on the
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proliferation of cultured tendon fibroblasts (Achilles), cell
survival following H2O2 stress was significantly increased.
The apparent lack of a direct effect was noted due to the
in vitro environment not mimicking the inherent environment
of a tendon in vivo.
Skeletal muscle healing
In addition to tendon and ligament healing, the positive
therapeutic effect of BPC 157 has also been extended and
applied to muscle injury models, both traumatic and sys-
temic. Following the compete transection of the quadri-
ceps muscle in rats, a traumatic definitive defect under
normal healing conditions would not be compensated
(Staresinic et al. 2006); it was reported that the systemic
delivery of BPC 157 promoted healing. More importantly,
the study demonstrated that this healing continued for a
sustained period (72 days) whilst maintaining the func-
tional restoration (Staresinic et al. 2006).
Novinscak et al. (2008) went on to compare the effec-
tiveness of both systemic (intraperitoneal) and local treat-
ment (as a thin cream layer) over a period of 14 days in
crushed muscle (gastrocnemius muscle complex) in rats.
BPC 157 significantly improved healing outcomes in both
sites of treatment: macroscopically, microscopically and
functionally, in addition to improving enzymatic activity
(a decrease in muscle proteolysis) (Farges et al. 2002).
The authors concluded that BPC 157 accelerated post-
injury skeletal muscle healing in addition to restoring full
muscle function that is similar to the finding in tendons
reported by Staresinic et al. (2006).
Pevec et al. (2010), akin to the tendon-to-bone healing
study of Krivic et al. (2006), proposed BPC 157 as an effective
treatment that could improve muscle healing, when adminis-
tered despite corticosteroid treatment, 6a-methylprednisolone,
following gastrocnemius muscular injury. With a similar
administrative procedure as previously outlined (topical
and intraperitoneal), corticosteroid administration was
shown to aggravate healing across all parameters. BPC
157, in contrast, induced faster rates of healing and induced
full functional restoration, which is also in agreement with the
aforementioned studies on tendons (Krivic et al. 2006). When
administered with corticosteroid, the restorative effects of
BPC 157 were not significantly affected in functional, macro-
scopic or histological measures.
In addition tomuscle injuries caused by direct trauma, there
have been a number of studies that have indicated that BPC
157 may have the ability to recover systemic muscular distur-
bances in response to induced nervous, electrolyte distur-
bances and/or skeletal muscle wasting (Petek et al. 1999;
Barisic et al. 2013; Klicek et al. 2013; Stambolija et al.
2016; Medvidovic-Grubisic et al. 2017; Kang et al. 2018).
Since systemic muscle pain is attributed to infection, autoim-
mune conditions, illness or side effects from medication, they
are considered to be more serious that stress or exercise-
related muscle injuries.
Fig. 1 Examples of successful administration mechanisms for the delivery of BPC 157; all routes, local and systemic, have been reported to have
positive healing outcomes
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Prolonged therapeutic benefits
In a study conducted by Hsieh et al. (2017), the authors aimed
to explore the proangiogenic and therapeutic effect of BPC
157. Demonstrated by chick chorioallantoic membrane
(CAM) and endothelial tube formation assays, both in vivo
and in vitro, BPC 157 was shown to increase both vessel
density and accelerate the recovery of blood flow in ischemic
muscle, indicating a promotional effect on angiogenesis.
Histological analysis was shown to confirm enhanced expres-
sion of vascular endothelial growth factor receptor 2
(VEGFR2) in rats treated with BPC 157. This was further
confirmed in vitro using human vascular endothelial cells.
BPC 157 was also shown to time-dependently activate the
VEGFR2-Akt-eNOS signalling pathway. The study therefore
demonstrates the pro-engiogenic effects of BPC 157 associat-
ed with VEGFR2 and VEGFR2-Akt-eNOS signalling.
It is worth noting that there does appear to be a trial admin-
istering BPC 157 (rectally administered) in human partici-
pants for the treatment and healing of acute to mild ulcerative
colitis (Veljaca et al. 2002; Veljaca et al. 2003); however,
details on the studies are limited and are not overly informa-
tive. Similarly, a pilot study in 2015, a clinical trial
(randomised) on 42 healthy human participants, receiving oral
(tablet form) dosages of BPC 157 was carried out
(Clinicaltrials.gov 2018): 0.25, 0.5, 1 and 2 μg/kg. The details
and results for this trial are still pending.
Although the mechanisms of action for BPC 157 are not
yet fully understood, both in the currently reviewed and other
surrounding literature, some light has been shed on a few
potential systems involving nitric oxide (NO) (Sikiric et al.
2014), the FAK-paxillin pathway (Chang et al. 2010), VEGF
(Hsieh et al. 2017) and the upregulation of growth hormone
(receptor) (Chang et al. 2014).
Comparison of published studies
General strengths seen in all of the studies previously reported
include the use of appropriate timelines for adequate stages of
healing to take place; longer study periods are given for soft
tissues that take longer to heal. All of the studies used both
in vivo and some form of in vitro methods of data collection in
order to observe different treatment effects, allowing for bio-
mechanical, functional (use of AFI index and load to failure),
macroscopic and microscopic histological analysis. All stud-
ies also reported the purity of BPC 157 in the methodologies
(99% high-pressure liquid chromatography (HPLC)).
Other strengths included allowing for appropriate time fol-
lowing administration of anaesthetic before biomechanical
and functional testing to ensure that there was no interference
between measures. The study conducted by Pevec et al.
(2010) also compared effects following the combination of
BPC 157 and corticosteroids; this allows a further understand-
ing of how well BPC 157 interacts with other agents and
therefore its applicability in post-operative cases or following
previous treatment. The studies specifically looking at soft
tissue healing also spread the assessment of healing markers
throughout the research period, involving data collection at
various time points, for example, 1, 4, 7, 10 and 14 days
throughout a 14-day study; this allows for a time-dependant
relationship to be highlighted (Staresinic et al. 2003;
Cerovecki et al. 2010; Pevec et al. 2010). Furthermore, differ-
ent methods of administration—oral, intraperitoneal and
topical—can be compared in order to establish a systemic
effect. All studies used a range of dosages, from 10 μg,
10 ng, 10 pg and 0 .1pg per different body masses (kg/bw)
and volumes (mL) BPC 157 in in vitro cultures (Staresinic
et al. 2003; Hsieh et al. 2017). This allows for a dose-
dependent relationship to be established, as well as allowing
the authors to gauge what dosages will affect micro vs macro
level measurements.
Some of the most robust studies and methodologies were
those that investigated the potential mechanisms surrounding
the healing effects of BPC 157. For example, in the study by
Novinscak et al. (2008), measures of enzyme activity were
used (creatine kinase, lactate dehydrogenase, aspartate amino-
transferase, alanine aminotransferase), allowing a gauge of
trauma response (proteolysis) and therefore the ability to fur-
ther understand the mechanisms of action. In the study con-
ducted by Chang et al. (2010), both MTT and Transwell filter
migration assays were used to establish cell proliferation of
tendon fibroblasts, along with staining (FITC-phalloidin) and
Western blot analysis to determine the protein expression and
activation of FAK and paxillin. Finally, Hsieh et al. (2017)
conducted chick chorioallantoic membrane (CAM), endothe-
lial tube formation and enzyme-linked immunosorbent assays.
One significant positive in this study is that they also used
laser Doppler scanning (recovery of blood flow in the ische-
mic muscle) to indicate the promotion of angiogenesis along-
side Western blot and real-time PCR for the expression of
VEGFR2.
Limitations of current studies
When considering the limitations, not all studies used the
same level of microscopic assessment, however, this is to be
expected; the studies looking more specifically at mechanistic
pathways of action will typically be focused on micro-analy-
sis, whereas those looking at the level of tissue healing on a
macro-scale will be focused on biomechanical and functional
measures.
Despite the use of rodents and small mammals being com-
monplace in research, in particular for the development of
novel therapeutic agents, caution still needs to be practiced
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when extrapolating research data to clinical applications.
Notwithstanding the impressive results that have been pub-
lished to date, there is still a requirement for successful human
trials to be completed prior to clinical translation. Since there
are obvious differences between rodent and human physiolo-
gy, it cannot be ignored that this may have a significant impact
on the efficacy and safety of (any) novel agents. However, it
should also be noted that BPC 157 is a peptide derived from
human gastric juices; therefore, some level of safety in human
subjects can be assumed. However, this still cannot be taken as
fact; thus, future studies should focus on elucidating as to
whether the reported benefits of BPC 157 extend beyond re-
search animals.
Another limitation of many of the cited studies was that
although the majority of the authors gave justification for re-
search (hypothesis specifically was not always outlined), they
did not appear to critically evaluate their own methodologies.
Finally, very few studies have touched upon any negatives
associated with the use of BPC 157 (having no known toxicity
level), as well as no obvious conflicts in literature-based ideas
being seen; this could be due to a lack of understanding re-
garding its mechanisms, as well as the fact that over the past
two decades, only a handful of studies have researched the
peptide (many from the same laboratory or group).
Moving forwards, it would be beneficial for further re-
search to progress to larger animal models. If more complex
animal systems were observed in their stages of healing (larger
animals with potentially more complex healing), this could
provide more insight into the healing capabilities seen in larg-
er mammals, such as humans. Another significant area of
research would be into mechanisms of action, shedding more
light on the supposed systemic healing capabilities of BPC
157. This could involve confirmation and further study of
the mechanisms already suspected to be impacted in the
healing process. A recently published review by Seiwerth
et al. (2018) used the current understanding from tendon, lig-
ament and bone and applied this to gastrointestinal tract
healing, which could provide a pathway for understanding
of the systemic healing capabilities for applications to other
tissues. Contemporary studies looking at animal models with
diseases that affect the vascular and endothelial systems have
also provided new insight into how BPC 157 works (Radeljak
et al. 2004; Sever et al. 2009; Duzel et al. 2017; Sikiric et al.
2018; Vukojević et al. 2018).
Despite the tumour-promoting effects of many growth fac-
tors and peptides, BPC 157 has been shown to inhibit and
counteract increased expression of VEGF and subsequent sig-
nalling pathways (Radeljak et al. 2004; Sever et al. 2009) thus
avoiding VEGF-tumorigenesis (Radeljak et al. 2004).
Furthermore, BPC 157 inhibits the growth of several tumour
lines and can counteract tumour cachexia (Kang et al. 2018).
Vukojević et al. (2018) and Duzel et al. (2017) recently
submitted works utilising BPC 157 for the treatment of
inferior caval vein ligatures and colitis in rats, respectively.
ICV is used to represent Virchow’s triad—hypercoagulability,
heamodynamic changes and endothelial injury/dysfunction—
and represents a subset of deep vein thrombosis (DVT).
Application of BPC 157, which has innate endotheium pro-
tective properties, counteracted direct vein injuries, thrombo-
sis and thrombocytopenia and prolonged bleeding (Vukojević
et al. 2018). Furthermore, additional detrimenal consequences
of ICV ligation were completely eliminated. When utilised as
a protoype cryoprotective agent, BPC 157 has been seen to
positively control blood vessel function in respsonse to
performation and obstruction, thus re-establishing blood flow
(Sikiric et al. 2018). Duzel et al. (2017) revealed that BPC 157
is fundamental to the tretament of colitis in rats; BPC 157
promotes the restoration of blood supply and vascular perfu-
sion with sparedmucosa. The integrity of the endothelium and
oxidative damage could be restored and reversed respectively,
which was linked to the increased expression and
internalisation of VEGFR2.
Although not currently prescribed for human use, it is im-
portant for athletes to proceed with caution when looking at
potential agents to prevent and treat injury. While not current-
ly on the WADA list of banned substances (Wada-ama.org
2018), due to what some individuals would term as the syn-
thetic nature of BPC 157, there may be issues associated with
the use of this peptide, as seen by some sport organisations.
Conclusion
The reviewed research uses indicators of healing success in
the form of in vitro, in vivo, macroscopic and microscopic
level measures in various models. There appears to be no
obvious conflict between studies surrounding the mechanisms
of BPC 157. However, this may be due to BPC 157’s clinical
infancy and the limited number of published clinical trial ar-
ticles exploring the use of the peptide. Nevertheless, all of the
studies to date that have tested BPC 157 as a treatment therapy
have demonstrated extremely positive healing effects for var-
ious injury types in a number of soft tissues. However, at
present, studies are predominantly limited to small animal
models (predominantly rodents) and the efficacy of BPC
157 is yet to be confirmed in human subjects. From the
recent literature, it can be said that BPC 157 appears to
avoid the majority of practical pitfalls for healing typically
seen using peptidergic growth factors. Although further
research is required in order to better understand its mech-
anisms and efficacy in practical settings, BPC 157 has the
potential to be developed as a new therapy to conservative-
ly treat or aid recovery following surgery in typically
hypovascular and hypocellular soft tissues such as tendon
and ligament tissue.
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